#DYK? #BurnWounds compromise the skin’s natural barrier, making it easier for #bacteria to enter and cause infections. Early detection and proper wound care are critical. #BurnAwarenessWeek #InfectionPrevention American Burn Association

🔥 Burn wounds aren’t just an injury—they’re a gateway to serious infections and global health challenges. This #BurnAwarenessWeek, we’re highlighting the hidden risks behind burns. #AMR #GlobalHealth recce.com.au/burn-wound-inf…

#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce positive patient data analysis in its Phase II clinical trial of RECCE® 327 Topical Gel (#R327G) for the treatment of Acute Bacterial Skin and Skin Structure Infections (#ABSSSI). Read

Responding to an emerging world health problem: Recce Pharmaceuticals has entered global #ClinicalTrials with a product that could be a game changer for the medical industry. ManufacturersMonthly Read the full article on pages 48 & 49: issuu.com/primecreativem…

Recce is in FierceBiotech! Our synthetic antibiotic R327 Gel is making headlines for its promising Phase 2 clinical trial results, offering a potential breakthrough for skin infections and #AMR. 📖 Read the full article: fiercebiotech.com/biotech/austra…

Reading alert: Bacteria Evolve Antimicrobial Resistance More Rapidly in Diabetes Model. Antibiotic-resistant strains of Staphylococcus aureus flourish in a #DiabeticInfection environment. Read the article here: technologynetworks.com/tn/news/bacter…

#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041. Read the full ann here: recce.com.au/company-announ…

Join Recce Pharmaceuticals for a live webinar today at 11 am AEDT as we dive into key clinical milestones and the future of our #AntiInfective programs. Hear from industry experts and get the latest insights! Secure your spot: bit.ly/4kjz1gf

In case you missed our webinar, don't worry! You can now view the full session on our YouTube channel. Watch the webinar here: youtube.com/watch?v=G3VgBh…

Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial. Read the full article here via The Australian: theaustralian.com.au/business/stock…

#ASXAnnouncement: Our latest investor presentation, "Commercialising a New Class of Synthetic Anti-Infectives," is now available! Learn more about the work that Recce's doing. View the full presentation here: recce.com.au/company-announ…

#ASX Ann - Recce Pharmaceuticals (ASX:RCE, FSE:R9Q), is pleased to announce it has received Human Research Ethics Approval (HREC) approval to build upon its Phase II Clinical Trial for the treatment of Diabetic Foot Infections (#DFI) by enrolling up to 20 additional patients with

Missed our Investor Webinar? Catch up on the latest clinical updates, our Phase 3 outlook & capital raise strategy as we progress toward commercialisation in 2026. 🔗Watch the full recording now on our YouTube: youtube.com/watch?v=hOw3vt…

#ASX Ann - Recce Pharmaceutical (ASX:RCE, FSE:R9Q), is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (Official USAMRIID), with partnership and funding

Learning about #handhygiene and #SafeGlove use matters. Help raise awareness this World Hand Hygiene Day to reduce the spread of infections between healthcare workers, patients and the wider community. Find out more: safetyandquality.gov.au/WHHD #WHHD ACSQHC World Health Organization (WHO) #NHHI

Not all #antibiotics are created equal. Our CSO Michele explains what makes Recce’s #AntiInfectives uniquely powerful in treating resistant #infections.

#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce it has received firm commitments to place all of the shortfall shares from the recent 1- for-6 pro-rata non-renounceable entitlement offer, the results of which were announced on 16 May

Recce Pharmaceuticals completes shortfall placement to raise $7.4 million Recce Pharmaceuticals Ltd #ASX #OTC #RCE #RECEF ow.ly/sui5106aQwF

Developer of a new class of synthetic anti-infectives, Recce Pharmaceuticals has received firm commitments to place the full shortfall from its recent 1-for-6 pro-rata non-renounceable entitlement offer. #ASX $RCE Recce Pharmaceuticals Ltd buff.ly/r0et5MA

Recce Pharmaceuticals Managing Director and CEO James Graham joins Stockhead TV following a bumper capital raising. #ASX #health $RCE